PERSPECTA

News from every angle

← Back to headlines

Syndax Pharmaceuticals Stock Analysis Amid Revised AML Market Estimates

An analysis questions whether Syndax Pharmaceuticals (SNDX) stock remains a viable biotech investment opportunity following recent revisions to Acute Myeloid Leukemia (AML) market estimates.

30 Jun, 13:06 — 30 Jun, 13:06
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual46d ago

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Read full article →

Related Stories

NUPRC Proposes Crude Swap Deals to Boost Nigerian Refinery Supply

14h ago

e-EFKA and DYPA Announce Payment Schedule Until August 21

22h ago

Joshua Kushner's Thrive Capital Invests $215 Million in Amazon

1d ago

Danish Apple Retailer Humac Enters Reconstruction, Stores Temporarily Closed

1d ago